BridgeBio Oncology Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBOT research report →
Companybbotx.com
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp.
- CEO
- Eli Wallace
- IPO
- 2025
- Employees
- 62
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $706.95M
- P/E
- -4.58
- P/S
- 0.00
- P/B
- 1.90
- EV/EBITDA
- -3.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.49%
- ROIC
- -45.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-134,044,000 · -80.47%
- EPS
- $-4.30 · -1034.78%
- Op Income
- $-145,819,000
- FCF YoY
- -14890.44%
Performance & Tape
- 52W High
- $14.87
- 52W Low
- $7.60
- 50D MA
- $8.81
- 200D MA
- $10.73
- Beta
- 0.19
- Avg Volume
- 334.84K
Get TickerSpark's AI analysis on BBOT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 10, 26 | Elmelech Idan | other | 758,222 |
| May 10, 26 | Beltran Pedro | other | 1,103,837 |
| Apr 1, 26 | Ben Yong | other | 1,047 |
| Apr 1, 26 | Beltran Pedro | other | 1,047 |
| Apr 1, 26 | Mehra Uneek | other | 524 |
| Apr 21, 26 | Cobo Marc | other | 0 |
| Apr 21, 26 | Cobo Marc | other | 129,090 |
| Apr 21, 26 | Cobo Marc | other | 25,125 |
| Apr 20, 26 | Elmelech Idan | other | 0 |
| Apr 20, 26 | Elmelech Idan | other | 129,678 |
Our BBOT Coverage
We haven't published any research on BBOT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BBOT Report →